Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

FDA Approves Drug for Cryptococcal Meningitis in HIV Patients

Summer 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Deerfield, Ill., July 5 (Reuters) -- The US Food and Drug Administration approved the antifungal drug AmBisome for the treatment of cryptococcal meningitis in HIV-infected patients, Fujisawa Healthcare Inc. and Gilead Sciences Inc. said Wednesday.

Cryptococcal meningitis is a life-threatening infection of the membranes lining the brain and spinal cord and occurs when a patient is exposed to the fungus cryptococcus neofor-mans. The organism can infect almost all organs in the body but most commonly causes disease of the spinal cord, skin or lungs.

The majority of people with cryptococcal meningitis have immune systems that are damaged by disease, such as AIDS, or suppressed by medications. It affects 5 to 10 percent of people infected with HIV.

AmBisome is also used to treat fungal infection in febrile neutropenic cancer patients, as well as patients with aspergillus, candida and cryptococcus species infections and visceral leishmaniasis.

Advertisement

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Women Alive. It is a part of the publication Women Alive Newsletter.
 
See Also
More on the FDA Drug Approval Process and Other Regulatory Issues

Tools
 

Advertisement